Impact of urgently initiated tele-prescription due to COVID-19 on glycemic control in patients with type 2 diabetes

Abstract

Background/Aims: Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than 13,000 people in South Korea by July 2020. To prevent spread of COVID-19, tele-prescription was permitted temporarily. This study investigated the impact of tele-prescription on glycemic control in patients with type 2 diabetes.

Methods: Glycated hemoglobin (HbA1c) concentrations were retrospectively analyzed in patients with type 2 diabetes who were treated with tele-prescription because of COVID-19 and those who were treated by face-to-face care (non-tele-prescription group) enrolled at the same period of time. Mean HbA1c concentrations and mean change in HbA1c concentration (Delta HbA1c) were compared in these two groups.

Results: The mean HbA1c levels of patients were significantly higher after than before the tele-prescription period (7.46% +/- 1.24% vs. 7.27% +/- 1.13%, p < 0.05). Mean Delta HbA1c was significantly higher in the tele-prescription than in the non-tele-prescription group (0.19% +/- 0.68% vs. 0.04% +/- 0.95%, p < 0.05). HbA1c was significantly greater in patients taking fewer oral hypoglycemic agents, no insulin, fewer comorbidities (e.g., coronary artery disease, cerebrovascular accident, and diabetic neuropathy), and higher baseline HbA1c.

Conclusions: Tele-prescription may worsen glycemic control in patients with type 2 diabetes during public health crises.